secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001628280-23-042223
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AVTX stockholders approve reverse stock split with ratio up to 1:250
--------------------------------------------------------------------

- Reverse stock split approved: 34.7M for, 31.6M against, 0.8M abstain (54.8% of votes cast).
- Board will determine final ratio between 1:5 and 1:250; split intended to maintain Nasdaq listing.
- Annual meeting quorum was 34.88% (67.1M of 192.4M shares outstanding).
- All five director nominees elected; Ernst & Young ratified as auditor for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/0001628280-23-042223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/avtx-20231220.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-042223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer